glp-1 and gip/glp-1 receptor agonists New strategies for the treatment of obesity metabolic dysfunctions Dual GLP-1/GIP Agonist | Tirzepatide

A large global retrospective cohort study (n=331,863 matched patients

Data from 81 selected studies were extracted and analyzed, focusing on mental health outcomes and reported adverse effects

Grading of Recommendations Assessment, Development and Evaluation (GRADE) showed moderate certainty for MACE, all-cause death and hospitalization for HF

A pattern of musculoskeletal injuries spurred researchers to conduct a study on whether using the popular weight-loss and diabetes drugs increased a persons risk of other health conditions.

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications that have gained significant attention in recent years for their ability to manage blood sugar levels and promote weight loss

David Kessler says the new weight-loss drugs are a powerful tool to fight obesity